NEW YORK ─ Biotherapeutics and reagents developer Avacta said on Tuesday that it has entered into a license agreement to incorporate its Affimer reagents, an alternative to antibodies, into a Biokit IVD test.
Under the terms of the agreement, Biokit, which is owned by Spanish diagnostics firm Werfen, will develop, manufacture, and commercialize a diagnostic immunoassay for an undisclosed analyte through original equipment manufacturer (OEM) partners.
Financial and other terms of the agreement were not disclosed.
Cambridge, UK-based Avacta noted that the agreement follows an extensive evaluation by Biokit of certain Avacta Affimer reagents to detect the analyte. Avacta added that it would receive royalties on future sales of any products that are commercialized following completion of product development and regulatory approvals.
"We can now move onto the next stage of development, incorporation of this technology into new products," Marta Palicio, innovation director of Barcelona, Spain-based Biokit, said in a statement. "We hope this is the first of many assays containing Affimer reagents which will be developed by Avacta."
Last month, Avacta inked an agreement to develop, manufacture, and distribute certain SARS-CoV-2 tests in collaboration with Bedfordshire, UK-based Mologic.